Scala Biodesign has secured $16 million in Series A funding to enhance its protein design platform, ScalaOS, aimed at revolutionizing the development of protein-based medicines. This Tel Aviv-based biotech company, which has raised a total of $21.5 million since its inception in 2022, is addressing a critical bottleneck in drug development: the inefficiencies associated with protein engineering. The funding round was led by Grove Ventures, with participation from several notable investors, including TLV Partners and the Israel Innovation Authority.

The significance of ScalaOS lies in its potential to drastically reduce the time and cost associated with developing biologics. Traditional methods often involve a tedious cycle of trial-and-error, where researchers must repeatedly adjust and test proteins that may not perform as needed. Scala’s platform leverages AI, physics-based modeling, and evolutionary data to streamline this process, allowing scientists to make informed design decisions early on. This shift could transform how complex therapies are engineered, ultimately accelerating the delivery of life-saving medicines to market. Early adoption by nine of the top 20 pharmaceutical companies, including a collaboration with Boehringer Ingelheim, underscores the platform’s practical impact, having already stabilized challenging drug targets in their pipeline.

For the longevity sector, the implications of Scala’s advancements are profound. As the field increasingly focuses on developing biologics for therapies targeting aging and healthspan extension, the need for efficient protein engineering becomes paramount. Scala’s technology could facilitate the creation of more effective, personalized treatments, thereby enhancing the feasibility of translating cutting-edge scientific discoveries into scalable, reliable therapies. This development marks a crucial step toward bridging the gap between innovative mechanisms in longevity research and their practical application in clinical settings.

Source: longevity.technology